‘Restless’ minister U T Khader hospitalized in Bengaluru

Tumakuru, Jan 8: RSS leader Kalladka Prabhakar Bhat stoked controversy on Wednesday by stating that 'Jawaharlal Nehru University (JNU) is full of traitors'.

He was addressing the media after taking part in a pro-CAA rally organised by National Citizens Forum near the office of the deputy commissioner of the district here.

Bhat said, “JNU is full of traitors. Congress and communist parties have been generating anti-nationals there. But there is no need to close the university down. Modi government will handle it.”

“Nationalism should be infused among the students there through love and trust. They should be made to realize what the truth is,” he said.

Bengaluru, May 1: Karnataka has reported 11 new cases of coronavirus, taking the State's count to 576, informed the Health Department on Friday.

Out of the total COVID-19 cases found in the State, 235 people have been discharged and 22 people have died.

"11 new COVID-19 cases have been confirmed in Karnataka from April 30, 5 pm till noon today, taking the total number of cases to 576, which includes 22 deaths and 235 discharges," said the State government COVID-19 bulletin.

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.